Shanghai, China--(Newsfile Corp. - November 21, 2025) - On the evening of August 27, the 2025 Frost & Sullivan Global Growth, Innovation & Leadership Awards, China Awards, and Best Practice Awards were grandly unveiled at the Frost & Sullivan Global Growth, Innovation and Leadership Award Ceremony 2025 and VIP Client Appreciation Gala Banouet.

Based on years of research and analysis of the global vaccine industry, as well as in-depth evaluation of relevant companies in the industry, Frost & Sullivan presented Everon Healthcare with the "2025 Global Recombinant Collagen Technology Innovation Leadership Award."

The award was presented to Mr. Jilin Yang, Founder and CEO of Everon Healthcare, by Hazmi Yusof, Senior Vice President and Managing Director of Frost & Sullivan Malaysia, together with Professor Yu Wang, Chairman of the China Foundation for Hepatitis Prevention and Control, Member of the Frost & Sullivan Global Expert Advisory Board, and recipient of the 2024 Frost & Sullivan Greater China Special Contribution Award.

Everon Healthcare

"2025 Global Recombinant Collagen Technology Innovation Leadership Award"

The award was presented to Mr. Jilin Yang, Founder and CEO of Everon Healthcare, by Hazmi Yusof, Senior Vice President and Managing Director of Frost & Sullivan Malaysia, together with Professor Yu Wang, Chairman of the China Foundation for Hepatitis Prevention and Control, Member of the Frost & Sullivan Global Expert Advisory Board, and recipient of the 2024 Frost & Sullivan Greater China Special Contribution Award.

Everon Healthcare is a distinguished Chinese company focused on the research, development and industrialization of recombinant triple-helical collagen.

Founded in 2014 and headquartered in Dongguan City, Everon Healthcare is a leading company in China, having achieved achieved large-scale production (3 × 30 tons) of Recombinant Type III Humanized Collagen with a true triple-helical structure and heat stability up to 90 °C. Driven by structural biology and synthetic biology, the company has built a full-chain product system covering "bioactive raw materials - medical devices - functional skincare", with multiple pipelines of Class II and Class III medical devices and cosmetic-grade raw materials that have been certified or are in the final registration stages.

With triple-helical collagen technology, Everon Healthcare is redefining the paradigms of aesthetic medicine and wound repair, bringing renewed vitality to both skin and life.

Everon Healthcare has formed a deep strategic collaboration with Jinmeiji Health Industry Group, leveraging its 30 years of industrial resources to continuously advance the clinical translation of recombinant collagen in aesthetic filling, wound care, and scalp anti-aging. Previously, the company's triple-helical collagen completed INCI international nomenclature registration and master file submission with the National Medical Products Administration (NMPA), enabling downstream enterprises to directly reference the documentation and accelerate product launch.

Everon Healthcare demonstrates distinct advantages in original innovation, with its indication layout covering diverse clinical needs in aesthetic medicine and wound repair.

The company's recombinant triple-helical collagen is designed with a humanized sequence, featuring key advantages such as high thermal stability, strong biological activity, and low immunogenicity, while ensuring batch-to-batch consistency that meets GMP requirements for large-scale production. Based on the characteristics of this core raw material, the company focuses on three major indication areas: aesthetic filling, wound repair, and scalp anti-aging, while simultaneously advancing raw material filing, medical device registration, and the commercialization of functional skincare products. In aesthetic medicine, it is developing long-lasting facial fillers. In wound care, it is creating Class II dressings to accelerate skin barrier repair. In scalp anti-aging, it plans to launch a collagen XVII-based drug device product for hair loss prevention and follicle strengthening. At present, Everon Healthcare is conducting multiple clinical studies, registration tests, and real-world studies in parallel, laying a solid foundation for the industrialization and globalization of recombinant collagen.

About the Frost & Sullivan Global Technology Innovation Leadership Award

The Frost & Sullivan Global Technology Innovation Leadership Award recognizes companies that have demonstrated outstanding performance and remarkable achievements in technological innovation, market potential, customer service, and brand leadership. Through in-depth interviews, industry analysis, and secondary research, the Frost & Sullivan team nominated a group of highly competitive and outstanding enterprises to an independent judging panel. This independent panel, comprising third-party investment and financing experts, financial specialists, bankers, and renowned entrepreneurs from publicly listed companies, conducted a rigorous evaluation of the nominated companies and decided to present the "2025 Global Recombinant Collagen Technology Innovation Leadership Award" to Everon Healthcare.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/275147